- 3502 N. Laurent St., Victoria, TX 77901
- [email protected]
- (361) 575-4713
LDN is an effective, safe and cost effective treatment which has been in active use for over 20 years on patients with autoimmune disorders. More and more evidence shows that LDN (3.0 – 4.5 mg taken orally at bedtime) promotes health supporting immune-modulation to reduce various oncogenic and inflammatory autoimmune processes. Since LDN upregulates endogenous opioid activity, it may also play a role in healing and repairing tissue. It may also promote stress resilience, exercise, social bonding & emotional well-being, as well as improve psychiatric problems like depression or autism.
When you take LDN at bedtime, it attaches to opioid receptors in your brain and in all types of immune cells, which will temporarily block endorphins from attaching. This signals your body to increase its level of endorphin production. The increased endorphin produced helps orchestrate the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells.
LDN also prevents overactivity of the immune system, which is the point of difficulty with autoimmune disorders, and can dull the release of inflammatory and neurotoxic chemicals in the brain.
LDN has been beneficial for a variety of conditions like ALS, Alzheimer’s disease, Autism, Celiac disease, Crohn’s disease, Fibromyalgia, Inflammatory bowel disease, Lupus, Multiple Sclerosis, Parkinson’s disease, Psoriasis, Rheumatoid arthritis, Ulcerative colitis, and Lyme disease.
Central Drug can compound LDN in various strengths. While ordinarily provided orally at a dose ranging between 1.5 – 4.5 mg per capsule, we are also able to formulate LDN into a transdermal cream or an oral suspension.
Our pharmacists compound LDN into dosage forms free from fillers, such as gluten, dyes, lactose, sugars, and other additives. Vegetable capsules are also available for patients who would like to avoid gelatin-based capsules.
Fibromyalgia
LDN has been found to be an effective, highly tolerable, and inexpensive treatment to reduce daily pain in patients with fibromyalgia. LDN has demonstrated a reduction of daily pain reported by patients. The only major reported side effects are vivid dreams and headaches.
LDN can provide significant benefit for the pain management of patients with fibromyalgia, with minimal side effects and a high degree of tolerance.
Crohn's Disease
LDN tested in patients with active Crohn’s disease demonstrated a significant decrease in CDAI (Crohn’s disease activity index) scores. Eighty-nine percent of patients exhibited a response to therapy and 67% achieved a remission. The most common side effect reported was sleep disturbances.
Multiple Sclerosis
A trial with LDN for patients with primary progressive multiple sclerosis (PPMS) demonstrated the safety and tolerability of LDN treatment. Secondary outcomes were the effectiveness displayed on spasticity, pain, fatigue, depression, and quality of life. There were no adverse events which interfered with daily living. LDN is associated with a significant improvement on mental health quality of life indices.
Pancreatic Cancer
A protocol utilizing LDN and intravenous alpha-lipoic acid (ALA/LDN) and a healthy lifestyle program has produced long-term survival without toxic side effects for patients with pancreatic cancer with or without metastases.
NOTE: We do not suggest that LDN be used in place of other treatment for cancer, but it may be a reasonable adjunctive therapy.
Side Effects
Sleep disturbances are rare, however some patients using LDN do report vivid dreams. To avoid this outcome, therapy can be started at a lower dose (1.5 mg) and slowly increased over a two month period.
